Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized clinical trial comparing daptomycin to vancomycin in the
Emergency Department (ED) treatment of complicated skin and skin structure infection in the
Rapid Diagnosis and Treatment Center (RDTC). In brief, a convenience sample of patients who
are admitted to the RDTC cellulitis protocol in the ED will be randomized to either
vancomycin, which is currently an accepted care standard in the RDTC cellulitis protocol, or
daptomycin, which is the experimental treatment in this study. The primary hypothesis is that
daptomycin treatment is as efficacious as standard therapy in the treatment of ED cellulitis.